Results for the Second Quarter and First Half 2023

Sales for the second quarter ended at MNOK 137.4 (MNOK 117.5), an increase of 16.9%. Sales for first half ended at MNOK 266.6 (MNOK 233.6), an increase of 14.1%.

‍

Currency-neutral sales of own products were up 4.0% for the quarter and 2.5% for the first half. Operating profit (EBIT) for the quarter is up 13.1% and ended at MNOK 42.2, an EBIT margin of 30.7% (MNOK 37.3 an EBIT margin of 31.8%). For the first half, EBIT is up 6.9% and ended at MNOK 75.7 an EBIT margin of 32.6% for the first half (MNOK 70.8 an EBIT margin of 35.3%). Medistim established direct sales organizations in both Canada and China in Q2 and continues to strengthen its organization worldwide.
‍

Download the full presentation and report, and watch the video recording from the webinar below.
‍

598394_Quarterly Report Q2 2023
‍

598394_Medistim ASA Q2 2023 Presentation

‍